Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma

Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma

Abstract Rationale Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis. The U.S. food and drug administration approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this treatment is frequent and fails to enhance the overall survival of...

Full description

Bibliographic Details
Main Authors: Ahmad Joshkon, Emeline Tabouret, Wael Traboulsi, Richard Bachelier, Stéphanie Simoncini, Sandrine Roffino, Carine Jiguet-Jiglaire, Bassam Badran, Benjamin Guillet, Alexandrine Foucault-Bertaud, Aurelie S. Leroyer, Françoise Dignat-George, Olivier Chinot, Hussein Fayyad-Kazan, Nathalie Bardin, Marcel Blot-Chabaud
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Acta Neuropathologica Communications
Subjects:
Soluble CD146
Biomarker
Therapeutic antibody
Bevacizumab
Glioblastoma
Online Access:https://doi.org/10.1186/s40478-022-01451-3

Internet

https://doi.org/10.1186/s40478-022-01451-3

Similar Items